Comparative Pharmacology
Head-to-head clinical analysis: BRINZOLAMIDE versus TRUSOPT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRINZOLAMIDE versus TRUSOPT.
BRINZOLAMIDE vs TRUSOPT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brinzolamide is a carbonic anhydrase inhibitor. It inhibits carbonic anhydrase II (CA-II) in the ciliary processes of the eye, reducing aqueous humor secretion and thereby lowering intraocular pressure.
Carbonic anhydrase inhibitor; decreases aqueous humor secretion by inhibiting carbonic anhydrase in the ciliary processes of the eye.
1 drop of 1% solution in the affected eye(s) twice daily.
One drop of 2% solution in affected eye(s) twice daily, approximately 12 hours apart.
None Documented
None Documented
Terminal elimination half-life: 111 days (due to extensive red blood cell binding); clinical context: steady-state reached after 8–12 weeks of dosing
Clinical Note
moderateBrinzolamide + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Brinzolamide."
Clinical Note
moderateBrinzolamide + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Brinzolamide."
Clinical Note
moderateBrinzolamide + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Brinzolamide."
Clinical Note
moderateBrinzolamide + Fluconazole
Terminal elimination half-life of dorzolamide in whole blood is approximately 4 months due to tight binding to carbonic anhydrase in red blood cells; however, the drug's clinical effect on intraocular pressure has a half-life of about 24 hours.
Renal: approximately 60% unchanged; biliary/fecal: minimal (<10%)
Renal excretion as unchanged drug: approximately 70% of a topically applied dose is excreted renally; the remainder is eliminated via biliary/fecal routes (30%). Following oral administration, renal excretion accounts for about 65-70%.
Category A/B
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor
"The metabolism of Fluconazole can be decreased when combined with Brinzolamide."